ExcelMale Consensus
Retatrutide has produced some of the largest average weight reductions reported in a Phase 3 obesity program, reaching 28.3% at 80 weeks and 30.3% at 104 weeks in a severe-obesity extension. The drug still has no FDA approval, no approved dosing instructions, and no proven cardiovascular outcome benefit.
For men interested in retatrutide, the important question is no longer whether the drug produces major weight loss. The key issues are how much dose is needed, how well side effects are tolerated, and how lean mass is protected during large reductions in body weight.
Key Takeaways
- Retatrutide activates GIP, GLP-1, and glucagon receptors.
- TRIUMPH-1 reported 28.3% average weight loss with 12 mg at 80 weeks.
- A TRIUMPH-1 extension reported 30.3% average weight loss at 104 weeks.
- The lower 4 mg dose produced 19.0% average weight loss with fewer adverse-event discontinuations.
- TRIUMPH-2 reported up to 20.8% average weight loss in people with type 2 diabetes.
- Benefits were also reported for HbA1c, waist circumference, triglycerides, blood pressure, sleep apnea, knee pain, and liver fat.
- Retatrutide reduces both fat mass and lean mass. Available DXA evidence does not show disproportionate lean-mass loss compared with other major obesity treatments.
- No clinical trial has established a special benefit from combining retatrutide with TRT.
- Dysesthesia, including abnormal skin sensitivity, tingling, burning, or numbness, has appeared repeatedly across Phase 3 studies.
- Retatrutide is still investigational. FDA states retatrutide is not eligible for compounding under federal law.
- Lilly plans a U.S. regulatory submission in the first quarter of 2027.
Retatrutide entered 2026 with impressive Phase 2 data. Five positive Phase 3 studies have since changed the discussion.
The strongest obesity trial reported 70.3 pounds of average weight loss with 12 mg over 80 weeks. A two-year extension involving people who started with a BMI of at least 35 reported an average loss of 85 pounds.
Those numbers deserve attention. They also need context because higher doses produced more gastrointestinal symptoms, dysesthesia, and treatment discontinuation.
What is retatrutide and how does it work?
Retatrutide is an investigational once-weekly peptide that activates GIP, GLP-1, and glucagon receptors in a single molecule.
Retatrutide was previously identified as LY3437943.
GLP-1 signaling affects appetite, satiety, gastric emptying, and glucose-dependent insulin secretion. GIP contributes to insulin secretion and metabolic regulation. Glucagon receptor activity influences hepatic metabolism, lipid metabolism, and energy expenditure.
The glucagon component separates retatrutide from semaglutide and tirzepatide.
| Medication | GLP-1 | GIP | Glucagon |
|---|---|---|---|
| Semaglutide | Yes | No | No |
| Tirzepatide | Yes | Yes | No |
| Retatrutide | Yes | Yes | Yes |
The term "GLP-3" sometimes appears in online discussions. GLP-3 is not a scientific drug class. Lilly describes retatrutide as a triple hormone receptor agonist.
Retatrutide has a half-life of roughly six days, supporting the once-weekly schedule studied in clinical trials.
How much weight loss did retatrutide produce in Phase 3 trials?
Retatrutide produced average weight reductions ranging from 12.7% to 28.7% across the major Phase 3 obesity populations reported so far.
| Trial | Population | Duration | Highest Reported Average Weight Loss |
|---|---|---|---|
| TRIUMPH-1 | Obesity or overweight without diabetes | 80 weeks | 28.3% with 12 mg |
| TRIUMPH-1 extension | Starting BMI of at least 35 | 104 weeks | 30.3% with 12 mg |
| TRIUMPH-4 | Obesity or overweight with knee osteoarthritis | 68 weeks | 28.7% with 12 mg |
| TRIUMPH-2 | Obesity or overweight with type 2 diabetes | 80 weeks | 20.8% with 12 mg |
| TRIUMPH-3 | Severe obesity with established cardiovascular disease | 80 weeks | 22.6% with 12 mg |
TRIUMPH-1 provides the clearest dose-response comparison.
At 80 weeks:
- 4 mg: 19.0% average weight loss, or 47.2 pounds.
- 9 mg: 25.9%, or 64.4 pounds.
- 12 mg: 28.3%, or 70.3 pounds.
- Placebo: 2.2%, or 5.5 pounds.
Among participants receiving 12 mg, 62.5% lost at least 25% of their initial weight.
45.3% lost at least 30%.
27.2% lost at least 35%.
One-third reached a BMI below 25.
Why does the statistical method used in TRIUMPH-1 matter?
The reported percentage depends partly on how investigators handle treatment interruptions and discontinuations.
The 28.3% headline result uses an efficacy estimand, which estimates outcomes under the planned treatment strategy.
The treatment-regimen analysis produced a 25.0% average reduction with 12 mg.
Both numbers are useful. The 25.0% estimate incorporates more treatment interruptions and discontinuations encountered during the trial.
What health effects occurred beyond retatrutide weight loss?
Retatrutide produced substantial improvements across several obesity-related metabolic and physical complications.
In TRIUMPH-1, reported changes included:
- Triglycerides decreased by as much as 41.0%.
- Non-HDL cholesterol decreased by as much as 24.2%.
- Systolic blood pressure decreased by as much as 12.3 mmHg.
- Waist circumference decreased by as much as 9.5 inches.
TRIUMPH-1 also included people with moderate-to-severe obstructive sleep apnea.
The apnea-hypopnea index fell by as much as 36.1 events per hour from a baseline of 58.6 events per hour.
This represents a 60.6% reduction.
TRIUMPH-4 studied people with obesity or overweight plus knee osteoarthritis. WOMAC knee-pain reductions approached 75% in the retatrutide groups.
TRANSCEND-T2D-1 provided the first peer-reviewed Phase 3 retatrutide diabetes results. HbA1c fell by as much as 2.0 percentage points after 40 weeks.
Up to 90% reached an HbA1c below 7%.
46% reached an HbA1c below 5.7%.
What happened to liver fat with retatrutide?
Retatrutide produced large reductions in liver fat in a randomized Phase 2a MASLD substudy.
At 24 weeks, average relative liver-fat reductions were:
- 1 mg: 42.9%.
- 4 mg: 57.0%.
- 8 mg: 81.4%.
- 12 mg: 82.4%.
- Placebo: a 0.3% increase.
At week 24, 86% of participants receiving 12 mg reached liver fat below 5%.
Later imaging showed further improvement, but the week-48 imaging sample was substantially smaller. The later percentage deserves more caution.
Does retatrutide reduce heart attacks or strokes?
No definitive cardiovascular outcome benefit has been established.
TRIUMPH-3 included exploratory cardiovascular analyses.
For MACE-5, 44 events occurred in the pooled retatrutide groups and 52 occurred with placebo.
The hazard ratio was 0.82, with a 95% confidence interval of 0.55 to 1.22.
For MACE-3, 27 events occurred with retatrutide and 23 with placebo.
The hazard ratio was 1.12, with a 95% confidence interval of 0.64 to 1.96.
Both confidence intervals include 1.0.
Retatrutide improved several cardiovascular risk markers, but improved risk markers do not prove fewer heart attacks, strokes, or cardiovascular deaths.
Larger cardiovascular and renal outcome trials are designed to answer this question.
What happens to muscle and lean mass during retatrutide treatment?
Retatrutide reduces both fat mass and lean mass during substantial weight loss.
A 2025 DXA substudy in people with type 2 diabetes reported reductions of up to 26.1% in total fat mass. Exploratory analyses found losses of up to 10.9 kg of total fat mass and up to 6.5 kg of lean mass.
The proportion of lean mass lost relative to total weight loss was similar to proportions reported with other major obesity treatments.
This distinction matters because DXA lean mass is not identical to skeletal muscle. Lean mass includes muscle, organs, connective tissue, glycogen, and body water.
Large reductions in body weight still create a practical muscle-preservation problem, especially for older adults and people starting with low muscle mass.
Useful priorities include:
- Progressive resistance training.
- Adequate protein intake.
- Avoiding unnecessarily severe calorie restriction.
- Monitoring strength and physical performance.
- Using body-composition testing when clinically useful.
For a broader discussion, see ExcelMale's guide to preventing muscle loss during GLP-1 treatment.
Does TRT prevent muscle loss during retatrutide treatment?
No clinical trial has shown that TRT prevents retatrutide-associated lean-mass loss.
There are also no randomized studies designed specifically around men receiving testosterone replacement therapy and retatrutide.
Major fat loss might alter insulin sensitivity, blood pressure, sleep apnea severity, lipid levels, SHBG, estradiol production, caloric requirements, and medication needs. A man losing 40 to 80 pounds might therefore find that parts of his broader TRT management require reassessment.
TRT should not replace adequate nutrition or resistance exercise.
Which retatrutide side effects appear most often?
Gastrointestinal symptoms remain the most frequent adverse effects reported with retatrutide.
In TRIUMPH-1, the 12 mg group reported:
- Nausea: 42.4%.
- Diarrhea: 32.0%.
- Constipation: 26.1%.
- Vomiting: 25.3%.
Adverse-event discontinuation increased with dose:
- 4 mg: 4.1%.
- 9 mg: 6.9%.
- 12 mg: 11.3%.
- Placebo: 4.9%.
The 4 mg result deserves more attention than it often receives.
Average weight loss reached 19.0%, while adverse-event discontinuation remained slightly below placebo.
What is dysesthesia and why does retatrutide cause concern about it?
Dysesthesia is an abnormal sensory experience involving symptoms such as tingling, burning, numbness, skin hypersensitivity, or unusual sensitivity to touch.
The effect has appeared repeatedly in Phase 3 retatrutide trials.
TRIUMPH-1 reported dysesthesia in:
- 5.1% with 4 mg.
- 12.3% with 9 mg.
- 12.5% with 12 mg.
- 0.9% with placebo.
TRIUMPH-4 reported a higher 20.9% rate with 12 mg.
Later Phase 3 trials reported lower rates, including 7.3% with 12 mg in TRIUMPH-2 and 6.4% in TRIUMPH-3.
Most reported cases were mild to moderate, and most resolved during treatment.
The mechanism is still uncertain.
What retatrutide dosing schedules were used in Phase 3 trials?
The Phase 3 program generally started retatrutide at 2 mg once weekly and increased the dose every four weeks.
| Target Dose | Trial Escalation |
|---|---|
| 4 mg | 2 mg, then 4 mg |
| 9 mg | 2 mg, 4 mg, 6 mg, then 9 mg |
| 12 mg | 2 mg, 4 mg, 6 mg, 9 mg, then 12 mg |
These are clinical-trial schedules, not prescribing instructions.
Retatrutide has no FDA-approved dose.
Online protocols involving 0.25 mg, 0.5 mg, split injections, twice-weekly use, microdosing, or peptide combinations were not established by the Phase 3 retatrutide program.
Is the highest retatrutide dose always the best dose?
No. TRIUMPH-1 shows a clear tradeoff between additional weight loss and additional adverse effects.
The 4 mg dose produced 19.0% average weight loss after only one escalation step.
The 12 mg dose produced 28.3%.
Higher doses also produced more nausea, vomiting, dysesthesia, and treatment discontinuation.
If retatrutide receives regulatory approval, dose selection will need to balance weight-loss goals, medical conditions, side effects, response, and individual tolerance.
More drug does not automatically mean a better clinical outcome.
Is retatrutide FDA approved or legally compounded in the United States?
No. Retatrutide remains an investigational drug as of September 2, 2026.
Lilly states that retatrutide has not received approval from any regulatory agency.
FDA also states that retatrutide is not eligible for compounding under federal law.
Anything sold outside a Lilly-sponsored clinical trial does not represent an FDA-approved retatrutide product with verified manufacturing, purity, potency, sterility, or labeling.
FDA has taken enforcement action against sellers marketing products labeled as retatrutide.
Lilly announced on July 23, 2026 that a U.S. Biologics License Application submission is planned for the first quarter of 2027.
A regulatory submission is not an approval.
No confirmed U.S. launch date exists, and no official commercial price has been announced.
What are ExcelMale members reporting about retatrutide?
ExcelMale members report substantial variation in appetite suppression, weight loss, gastrointestinal tolerability, fatigue, sleep, food preferences, alcohol cravings, libido, and sensory symptoms.
Several members describe experiences that differ from semaglutide or tirzepatide. Others report dose-response problems or side effects that caused them to stop treatment.
These reports are useful for identifying questions worth studying, but they do not establish efficacy rates, safety rates, dosing instructions, sterility, product purity, or drug combinations.
This distinction is especially important because members using products outside Lilly trials do not have access to an FDA-approved retatrutide product.
Read ExcelMale Member Experiences with Retatrutide for community reports separated from clinical-trial evidence.
What questions do readers ask most about retatrutide?
Is retatrutide a GLP-3 drug?
No. GLP-3 is an inaccurate internet nickname. Retatrutide activates GIP, GLP-1, and glucagon receptors.
How much weight did people lose with retatrutide?
The 12 mg group in TRIUMPH-1 lost an average of 28.3% at 80 weeks. Participants with a starting BMI of at least 35 who entered the extension reached 30.3% average weight loss at 104 weeks.
Does retatrutide preserve muscle?
Retatrutide reduces fat mass and lean mass. Current DXA evidence suggests the proportion of lean-mass loss is similar to other major obesity interventions rather than disproportionately high.
Does TRT prevent muscle loss from retatrutide?
No clinical trial has demonstrated that TRT prevents retatrutide-associated lean-mass loss.
Is retatrutide better than tirzepatide or semaglutide?
No Phase 3 head-to-head obesity trial has established superiority over tirzepatide or semaglutide.
Separate trials differ in study populations, duration, diabetes status, adherence, discontinuation rates, lifestyle programs, and statistical methods. Cross-trial percentages do not provide a clean head-to-head comparison.
What retatrutide doses were studied?
The Phase 3 obesity program studied maintenance targets of 4 mg, 9 mg, and 12 mg. Participants generally began at 2 mg weekly and escalated every four weeks according to the trial protocol.
Is the Phase 3 dosing schedule an approved retatrutide protocol?
No. These doses describe clinical research protocols. Retatrutide has no FDA-approved dosing instructions.
Is compounded retatrutide legal in the United States?
FDA states that retatrutide is not eligible for compounding under federal law.
When is retatrutide expected to reach the FDA?
Lilly plans to submit retatrutide for U.S. regulatory review in the first quarter of 2027. No approval date or commercial launch date has been confirmed.
Which ExcelMale discussions add useful real-world context?
- Retatrutide Peptide: Dosing, 28% Weight Loss and Side Effects
- ExcelMale Member Experiences with Retatrutide
- Looking for Retatrutide Experiences
- The Ultimate GLP-1 Guide: Weight Loss, Side Effects and Sarcopenia Risk
- GLP-1 Medications: Preventing Muscle Loss During Treatment
- ExcelMale Weight Loss Options Forum
What matters most as retatrutide moves toward FDA review?
The next important retatrutide question is less about maximum weight loss and more about the lowest dose that delivers enough weight loss with acceptable long-term tolerability.
TRIUMPH-1 makes this issue hard to ignore. The 4 mg dose produced 19.0% average weight loss while adverse-event discontinuation was 4.1%. The 12 mg dose increased average weight loss to 28.3%, but discontinuation rose to 11.3%.
For some patients, another nine percentage points of weight loss might justify the additional exposure and side effects. For others, a lower maintenance dose might produce a better clinical balance.
Regulatory approval will answer only part of the retatrutide story. Long-term practice will need to determine how physicians balance weight loss, metabolic improvement, muscle preservation, side effects, cost, and maintenance dosing over years rather than months.
Which sources support this retatrutide guide?
1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389:514-526. doi:10.1056/NEJMoa2301972
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. 2023;402:529-544. doi:10.1016/S0140-6736(23)01053-X
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine. 2024;30:2037-2048. doi:10.1038/s41591-024-03018-2
4. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes. The Lancet Diabetes & Endocrinology. 2025;13:674-684. doi:10.1016/S2213-8587(25)00092-0
5. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide in people with type 2 diabetes, TRANSCEND-T2D-1. The Lancet. 2026;407:2402-2413. doi:10.1016/S0140-6736(26)00967-0
6. Eli Lilly and Company. TRIUMPH-4 Phase 3 results. December 11, 2025. TRIUMPH-4 Phase 3 results
7. Eli Lilly and Company. TRIUMPH-1 Phase 3 results. May 21, 2026. TRIUMPH-1 Phase 3 results
8. Eli Lilly and Company. TRIUMPH-1, obstructive sleep apnea, knee osteoarthritis, and TRANSCEND-T2D-1 results. June 6, 2026. Additional Phase 3 results
9. Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 Phase 3 results. July 23, 2026. TRIUMPH-2 and TRIUMPH-3 results
10. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Updated 2026. FDA information on unapproved GLP-1 drugs and retatrutide
Medical Disclaimer
This article is for educational purposes and does not provide individual medical advice.
Retatrutide remains investigational and has not received FDA approval or approval from another regulatory agency as of September 2, 2026. No FDA-approved retatrutide product, prescribing information, dosing schedule, or commercial formulation exists.
Clinical-trial doses discussed in this article document research protocols. They are not instructions for self-treatment.
Anyone seeking treatment for obesity, diabetes, sleep apnea, metabolic disease, or weight-related complications should work with a qualified healthcare professional using approved therapies and appropriate medical monitoring.
Who wrote this article?
Nelson Vergel is the founder of ExcelMale.com and an author and men's health advocate focused on testosterone replacement therapy, hormone health, sexual health, metabolic health, and healthy aging.
He is the author of Testosterone: A Man's Guide, Beyond Testosterone, The hCG Advantage, and The Peptide Consensus.
Updated September 2, 2026.
What is ExcelMale?
ExcelMale.com is a men's health community with more than 24,000 members and over 20 years of archived discussions covering testosterone replacement therapy, hormones, sexual health, weight management, peptides, laboratory testing, exercise, nutrition, and healthy aging.
The forum combines published medical evidence with moderated community discussions and long-term patient experience.
Last edited:
